G01N 2800/2885
Duchenne dystrophy
G01N2800/2885 (Duchenne dystrophy) appears on 19 US grants and 17 published applications in this corpus.
Search patents in G01N- Granted patents
- 19
- Published applications
- 17
- Assignees
- 22
- Inventors
- 68
- Latest grant
- 1 May 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 2 | 3 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 2 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Therapeutic and diagnostic methods involving biglycan and utrophin1 May 2018US 9,958,458 B2Brown University
- Methods for diagnosing, prognosing and treating muscular dystrophy16 Jan 2018US 9,867,866 B2Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
- Methods for treating muscular dystrophy4 Jul 2017US 9,694,049 B2Board of Regents of the Nevada System of Higher Education On Behalf of the Unitversity of Nevada, Reno
- Biglycan and related therapeutics and methods of use8 Apr 2014US 8,691,766 B2Brown University Research Foundation
- Protein markers for the diagnosis and prognosis of ovarian and breast cancer29 May 2012US 8,187,889 B2Ludwig Institute for Cancer Research
- Antibodies and methods of using thereof26 Dec 2024US 2024/0425572 A1REGENXBIO Inc.
- Methods for measuring dystrophin in tissue samples4 Jan 2024US 2024/0003898 A1Pfizer Inc.
- Compositions and methods for identifying, modulating and monitoring drug targets in muscular disease4 Oct 2018US 2018/0284136 A1SomaLogic, Inc.
- Methods for diagnosing, prognosing and treating muscular dystrophy14 Sep 2017US 2017/0258873 A1Board of Regents of the Nevada System of Higher Education, on Behalf of the Univ. of Nevada, Reno
- Compositions and methods for identifying, modulating and monitoring drug targets in muscular disease10 Nov 2016US 2016/0324927 A1SomaLogic, Inc.
Most cited
By later US patents
- Methods and compositions for targeting compounds to muscle70US 6,329,501 B1Auburn University · 2001
- Nucleic acid encoding dystrophin-associated protein32US 5,449,616 AUniversity of Iowa Research Foundation · 1995
- Probes for and nucleic acid encoding the muscular dystrophy protein, dystrophin30US 5,621,091 AChildren's Medical Center Corporation · 1997
- Muscular dystrophy protein, dystrophin13US 5,239,060 AChildren's Medical Center Corporation · 1993
- Diagnosis of autosomal muscular dystrophy11US 5,308,752 AUniv. of Iowa Research Foundation · 1994